Why Hims & Hers (HIMS) rose 6.47%
Hims & Hers (HIMS) rose 6.47% on November 12, 2026 — US curb easing opens unapproved peptide sales.
What happened
Hims & Hers rose 6.5% after saying it will offer unapproved peptides following a US easing of curbs on those products.
Why it moved
Looser enforcement widens the range of products Hims can sell, which can support near-term revenue growth. For a high-growth telehealth name, a clear new product line is the kind of catalyst that moves the stock quickly.
Why it matters
Hims is a leading name in the Meme Stocks theme, where stocks trade on sharp narrative shifts and retail momentum.
What would break the thesis
If regulators reverse course or block the peptide offering, the upside disappears. Also watch whether the product actually launches and whether early sales back up the revenue case.
Sources
- Hims & Hers to offer unapproved peptides after US eases curbs — Investing.com
- Canaccord reiterates Hims & Hers stock rating after Q3 results — Investing.com